Endothelial Vulnerability Beyond Topoisomerase IIβ Target Engagement in Cardiomyocytes
Canonical mechanisms of anthracycline-induced cardiac dysfunction focus on doxorubicin-mediated poisoning of Topoisomerase IIβ in terminally differentiated myocytes [1]. This conventional focus presumes that double-strand DNA breaks and secondary necrosis initiate myocardial failure [2]. However, clinical reductions in left ventricular ejection fraction occur late, following extensive, irreversible myocardial architecture collapse [1][3]. Emerging multi-omic profiling reveals that cardiac microvascular endothelial cells (CMECs) suffer primary damage well before measurable troponin release appears in peripheral circulation [1]. CMECs in the primary human cardiac microvascular endothelial cell culture system display an acute vulnerability threshold when exposed to sub-micromolar doxorubicin concentrations between 0.2 and 1.0 μM [2]. In contrast to adult cardiomyocytes, which maintain compensatory catalase and glutathione peroxidase reserves, CMECs exhibit low baseline expression of hydrogen peroxide-detoxifying enzymes [1][3].
As summarized in Table 1, distinct pharmacokinetic thresholds, membrane dynamics, and inflammatory activation kinetics differentiate microvascular endothelial susceptibility from classic cardiomyocyte mechanical failure. Exposure to 0.5 μM doxorubicin induces pronounced upregulation of vascular cell adhesion molecule-1 (VCAM-1) in cardiac vascular beds within hours of administration [1]. This surface reprogramming promotes early granulocyte attachment and microvascular obstruction prior to global contractile decline [1][2]. In the C57BL/6J mouse model, systemic administration alters endothelial drug distribution and vascular permeability across capillary networks, disrupting local homeostasis [2][3]. The rapid onset of endothelial dysfunction establishes the cardiac microvasculature as the primary cellular target mediating progressive anthracycline cardiotoxicity [1][3].
Mitochondrial Redox Cycling and Priming of the NLRP3 Nucleation Complex
Intracellular uptake of doxorubicin across the endothelial plasma membrane leads to preferential accumulation within mitochondrial inner membranes [4][5]. The quinone moiety of the anthracycline core undergoes one-electron reduction catalyzed by mitochondrial Complex I (NADH dehydrogenase) and endothelial NADPH oxidases, specifically NOX4 [4]. This enzymatic reduction forms an unstable semiquinone radical intermediate [4][5]. Rapid auto-oxidation of the semiquinone regenerates the parent quinone compound while transferring electrons directly to molecular oxygen, generating a sustained efflux of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) [4]. Hydroxyl radical generation via trace-iron-dependent Fenton chemistry accelerates oxidative scission of cardiolipin, disrupting inner mitochondrial membrane potential (ΔΨ_m) [4][5].
Accumulating reactive oxygen species induce oxidative modifications on mitochondrial DNA, yielding 8-hydroxy-2'-deoxyguanosine-rich fragments (ox-mtDNA) that extrude through permeability transition pores into the endothelial cytosol [4][6]. Cytosolic ox-mtDNA engages Toll-like receptor 4 (TLR4) signaling networks, triggering IκB kinase activation and NF-κB p65 nuclear translocation [5][6]. This pathway represents Signal 1 priming, driving transcriptional expression of pro-IL-1β, pro-IL-18, and sensor protein NLRP3 [4][6]. Simultaneously, doxorubicin activates Signal 2 through cellular potassium efflux via TWIK2 two-pore domain potassium channels [4]. Intracellular K+ depletion facilitates structural binding between the non-catalytic domain of NIMA-related kinase 7 (NEK7) and the leucine-rich repeats of NLRP3 [4][6]. This direct interaction triggers conformational rearrangement of the NLRP3 central NACHT domain, exposing oligomerization interfaces essential for nucleation [4].
Caspase-1 Processing Kinetics and Gasdermin D Pore Architecture
Following NEK7 licensing, the pyrin domain (PYD) of nucleated NLRP3 recruits the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) via homotypic PYD-PYD interactions [6][7]. ASC nucleates into macroscopic helical filaments that coalesce into a solitary, dense supramolecular assembly termed the ASC speck [7]. The exposed caspase activation and recruitment domain (CARD) of assembled ASC binds the CARD motif of pro-Caspase-1 [7][8]. High local proximity induces intermolecular dimerization and auto-catalytic processing of the 45 kDa zymogen into active p20 and p10 subunits, forming the catalytically competent (p20/p10)2 heterotetramer [7]. Active Caspase-1 exhibits high catalytic efficiency toward Gasdermin D (GSDMD), executing site-specific endopeptidase cleavage at the Asp275 residue situated within the flexible interdomain linker [7][8].
Cleavage at Asp275 liberates the active 31 kDa GSDMD N-terminal domain (GSDMD-N) from its auto-inhibitory C-terminal regulatory domain [7][8]. In the AC16 human cardiomyocyte cell line and adjacent microvascular endothelium, doxorubicin exposure markedly increases GSDMD-N abundance [7][8]. Uncaged GSDMD-N exposes basic, amphipathic surface patches that bind phosphoinositides, specifically phosphatidylinositol 4,5-bisphosphate [PI(4,5)P₂] and phosphatidylserine, on the inner leaflet of the plasma membrane [7]. Membrane insertion drives oligomerization of 16 to 28 GSDMD-N protomers into an asymmetric, ring-shaped transmembrane barrel possessing an inner conduit diameter of 10 to 14 nm [8]. These stable conduits alter membrane permeability by permitting unhindered flux of water and ions down electrochemical gradients, resulting in rapid loss of cellular homeostasis [7][8].
Microvascular Permeability Collapse and Paracrine Myocardial Disruption
GSDMD conduit insertion rapidly dissipates transmembrane ionic gradients, triggering rapid intracellular sodium and water influx driven by cytoplasmic oncotic pressure [7][8]. The resulting cellular swelling culminates in plasma membrane rupture and the release of lactate dehydrogenase [7]. Concurrently, GSDMD pore formation initiates targeted endopeptidase-mediated disassembly of endothelial adherens junctions [1][3]. Immunofluorescence analysis of continuous endothelial monolayers confirms profound cleavage and internalization of vascular endothelial cadherin (VE-cadherin/CD144) alongside destabilization of zonula occludens-1 (ZO-1) tight-junction networks [1]. In vitro Transwell barrier assays using HCMECs establish that 0.5 μM doxorubicin causes a steep decline in transendothelial electrical resistance (TEER) within 12 hours, preceding structural injury in co-cultured myocytes [1][3].
Membrane disruption enables immediate, uncontrolled extrusion of mature IL-1β (17 kDa) and IL-18, processed by Caspase-1 from their immature pro-forms [7][8]. In the Sprague-Dawley rat model, anthracycline treatment generates high local concentrations of mature IL-1β in cardiac interstitial spaces [1][5]. Released IL-1β engages the type I interleukin-1 receptor (IL-1R1) on neighboring myocytes, initiating MyD88-dependent signal cascades that promote calcineurin activation and NFAT dephosphorylation [5][6]. This paracrine signaling axis suppresses sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) expression, impairing calcium reuptake during diastole [1][8]. Furthermore, unbuffered microvascular barrier breakdown facilitates unrestricted extravasation of circulating anthracyclines directly into the myocardial parenchymal space, compounding myocyte toxicity [1][2].
Therapeutic Intervention Nodes: Direct Inhibitors of Inflammasome Components
Elucidation of the endothelial pyroptotic pathway reveals targeted intervention opportunities to mitigate anthracycline cardiotoxicity without blunting oncological efficacy [4][7]. Direct pharmacological inhibition of the NLRP3 sensor represents an effective upstream strategy [4][6]. Small-molecule inhibitors MCC950 (CRID3) and dapansutrile (OLT1177) bind the ATP-hydrolysis site within the NACHT domain of NLRP3 with high affinity (IC50 ~ 7.5 nM for MCC950) [4]. These agents lock the sensor in an inactive, closed conformation, blocking ATP hydrolysis, NEK7 recruitment, and ASC speck oligomerization [4][6]. In H9c2 rat myoblast cell line cultures and primary microvascular endothelial models, pre-treatment with MCC950 blocks doxorubicin-induced Caspase-1 activation and suppresses IL-1β release [4][7].
Interventions targeting downstream pore execution provide alternative cytoprotection [7][8]. Disulfiram, an FDA-approved compound repurposed as an anti-pyroptotic agent, covalently modifies Cys191 on human GSDMD (Cys192 in rodents) via dithiocarbamylation [7]. This modification prevents GSDMD-N protomers from inserting into the plasma membrane without impairing upstream Caspase-1 maturation [7][8]. Similarly, necrosulfonamide binds GSDMD directly, halting functional pore assembly [8]. Upstream redox interception also limits inflammasome priming [4][6]. Mitochondria-targeted antioxidants, such as MitoTEMPO, selectively scavenge mitochondrial superoxide, suppressing ox-mtDNA formation [4]. Although the systemic iron chelator dexrazoxane remains the sole clinically approved cardioprotective agent for anthracyclines, its activity stems from Topoisomerase IIβ catalytic modulation and iron chelation [4][7]. Combining dexrazoxane with targeted NLRP3 or GSDMD inhibitors presents a synergistic paradigm to protect both the microvascular endothelium and contractile cardiomyocytes against doxorubicin-mediated damage [4][7][8].